Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Tirzepatide and Work: Survey Findings
A survey of 518 US employees starting tirzepatide found strong support for obesity-drug coverage, but it did not measure treatment effects.
Tirzepatide and Exercise Anaphylaxis
A case report links tirzepatide with exercise-induced anaphylaxis in one patient, with no recurrence after the medicine was stopped.
GLP-1 Weight Loss Depended on AgRP Neurons
A 2026 mouse study found that disrupting AgRP neurons weakened the full weight-lowering response to GLP-1 receptor agonists in females.
Incretins and MASLD: What 24 Trials Found
A 2026 review found better liver enzymes and MASH resolution with incretin therapies, but fibrosis regression remained uncertain.
Semaglutide in type 1 diabetes: ADJUST-T1D
ADJUST-T1D found better glucose-and-weight outcomes with semaglutide in selected adults, but it did not test long-term cardiovascular benefit.
Tirzepatide anhedonia: three case reports
Three patients reported improved motivation after tirzepatide dose reduction, but the uncontrolled case series cannot establish frequency or causation.
GLP-1 drugs in dermatologic disease
A 2026 review links GLP-1 drugs with inflammatory skin disease, but its clearest clinical evidence comes from one psoriatic arthritis trial.
GLP-1 drugs and diabetic foot reports
A 2026 FAERS analysis found a lower proportional reporting signal for diabetic foot complications, but it did not measure patient incidence or prove protection.
MASH fibrosis treatment panel update
An expert panel maps how semaglutide and resmetirom may fit MASH care, while long-term outcomes and direct comparisons remain open.
Retatrutide access opens case by case
A US registry now lists individual-patient retatrutide expanded access as available under narrow criteria. It is not approval or broad availability.
Semaglutide plus exercise in rats
A four-week rat study found partly distinct metabolic effects from semaglutide and aerobic training, with no direct evidence for menopausal women.
Semaglutide neuropathy case report
A single case found improved corneal nerve measurements after semaglutide, while neuropathy symptoms and disability scores stayed unchanged.